Efficacy and safety of talimogene laherparepvec versus granulocyte-macrophage colony-stimulating factor in patients with stage IIIB/C and IVM1a melanoma: subanalysis of the Phase III OPTiM trial

OBJECTIVES: Talimogene laherparepvec is the first oncolytic immunotherapy to receive approval in Europe, the USA and Australia. In the randomized, open-label Phase III OPTiM trial (NCT00769704), talimogene laherparepvec significantly improved durable response rate (DRR) versus granulocyte-macrophage...

Descripción completa

Detalles Bibliográficos
Autores principales: Harrington, Kevin J, Andtbacka, Robert HI, Collichio, Frances, Downey, Gerald, Chen, Lisa, Szabo, Zsolt, Kaufman, Howard L
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2016
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5119624/
https://www.ncbi.nlm.nih.gov/pubmed/27895500
http://dx.doi.org/10.2147/OTT.S115245

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5119624/
https://www.ncbi.nlm.nih.gov/pubmed/27895500
http://dx.doi.org/10.2147/OTT.S115245

Ejemplares similares